EP2167526A1 - Purification du facteur viii à l'aide d'une résine en mode mixte ou multimodal - Google Patents
Purification du facteur viii à l'aide d'une résine en mode mixte ou multimodalInfo
- Publication number
- EP2167526A1 EP2167526A1 EP08786090A EP08786090A EP2167526A1 EP 2167526 A1 EP2167526 A1 EP 2167526A1 EP 08786090 A EP08786090 A EP 08786090A EP 08786090 A EP08786090 A EP 08786090A EP 2167526 A1 EP2167526 A1 EP 2167526A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- factor viii
- protein
- salt
- purification
- ethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000301 factor viii Drugs 0.000 title claims abstract description 68
- 238000000746 purification Methods 0.000 title claims abstract description 65
- 239000011347 resin Substances 0.000 title claims abstract description 27
- 229920005989 resin Polymers 0.000 title claims abstract description 27
- 102000001690 Factor VIII Human genes 0.000 claims abstract description 97
- 108010054218 Factor VIII Proteins 0.000 claims abstract description 96
- 238000000034 method Methods 0.000 claims abstract description 61
- 238000011068 loading method Methods 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 239000003446 ligand Substances 0.000 claims abstract description 21
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 17
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 107
- 102000004169 proteins and genes Human genes 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 46
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 45
- 150000003839 salts Chemical class 0.000 claims description 41
- 239000012149 elution buffer Substances 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 21
- 239000000356 contaminant Substances 0.000 claims description 16
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 15
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 13
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 11
- 229910001424 calcium ion Inorganic materials 0.000 claims description 11
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 11
- 229920000053 polysorbate 80 Polymers 0.000 claims description 11
- 230000009467 reduction Effects 0.000 claims description 10
- 239000011534 wash buffer Substances 0.000 claims description 10
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 4
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 9
- 230000008569 process Effects 0.000 abstract description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract description 2
- 239000003114 blood coagulation factor Substances 0.000 abstract description 2
- 235000002639 sodium chloride Nutrition 0.000 description 34
- 230000000694 effects Effects 0.000 description 23
- 238000010828 elution Methods 0.000 description 19
- 238000003306 harvesting Methods 0.000 description 15
- 239000000872 buffer Substances 0.000 description 13
- 230000003993 interaction Effects 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000006167 equilibration buffer Substances 0.000 description 9
- 239000006172 buffering agent Substances 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 238000012433 multimodal chromatography Methods 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 238000011067 equilibration Methods 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000005498 polishing Methods 0.000 description 5
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940105778 coagulation factor viii Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000012539 chromatography resin Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- -1 e.g. Chemical compound 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 102000057593 human F8 Human genes 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QLAGGJISLHPJHC-UHFFFAOYSA-N 4-sulfanyl-1h-benzimidazole-2-sulfonic acid Chemical compound C1=CC(S)=C2NC(S(=O)(=O)O)=NC2=C1 QLAGGJISLHPJHC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 108010089996 B-domain-deleted factor VIII Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000005233 VisuLize Factor VIII Antigen Kit Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940031675 advate Drugs 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000603 anti-haemophilic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940083810 helixate Drugs 0.000 description 1
- 208000002085 hemarthrosis Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960000900 human factor viii Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 108010025139 recombinant factor VIII SQ Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
Definitions
- the present invention is related to a method for purifying a recombinant protein using a multimodal or mixed mode resin containing ligands which comprise a hydrophobic part and a negatively charged part.
- the protein of interest is a coagulation factor, particularly relevant to the purification of compositions of recombinant Factor VIII.
- Human Factor VIII also known as antihaemophilia factor or FVIII:C is a human plasma protein consisting of two polypeptides with light chain molecular weight of 80,000 daltons and a heavy chain molecular weight variable from 90,000 to 220,000. It is considered as one of the key cofactors in the coagulation pathway necessary for the conversion of Factor X into its active form Factor Xa.
- Factor VIII circulates in plasma as a non-covalent complex with von Willebrand Factor (also known as FVIII : RP).
- Hemophilia a bleeding disorder is caused due to abnormal levels of Factor VIII. Factor VIII levels below 20% normal may result in hemophilic condition in humans. A drop in the levels of less than 1% of Factor VIII leads to severe bleeding disorder, with spontaneous joint bleeding being the most common symptom.
- isolation and purification of Factor VIII has been from a plasma derived source (cryoprecipitate).
- Purification procedures from plasma-derived sources include those exploring the use of immunoaffinity purification using polyclonal and monoclonal antibodies for the purification of FVIII.
- the Factor VIII effluent contains some residual antibody due to leaching from the support matrix, which may result in antigenicity during ultimate use, i.e when introduced into human or animal system.
- Purification procedures exploring the use of ion exchange chromatography on e.g. agarose beads have also been used for purification of factor VIII from plasma. These methods, however, often suffer from certain levels of contamination of the resulting FVIII: C.
- the contaminants in recombinantly produced protein may include secreted proteins in the culture medium, media components, cell lysates, unwanted proteins produced by the cells and the nucleic acids.
- the aqueous source materials in which the polypeptides of interest are found are furthermore often seen to be contaminated with one or more viruses.
- Techniques for inactivating viruses in polypeptide mixtures are known in the art, such as e.g. chemical methods, using solvent/detergent solutions, irradiation methods, or thermal methods, but attempts to combine such techniques with known polypeptide purification processes have produced methods with a multiplicity of steps unsuitable for large-volume production. It is also important to exert caution in that the used viral-inactivating agents do not denature the protein or are difficult to separate from the protein of interest.
- Nordfang et al. Thrombosis and Haemostasis 58(4), 1043-1048 (1987) describes a separation using an antibody resin and a buffer containing 50% ethylene glycol and high salt.
- the purification of a recombinant protein expressed in mammalian cell system is typically performed in several steps.
- the different steps are usually separated into capture, intermediate and polishing.
- the objective of the capture step is two-fold; a) to obtain the target protein in a stable solution form and b) to reduce the volume (i.e. obtaining a solution concentrated with respect to protein content compared to the solution loaded onto the column ("the loading").
- the latter step (reduction of volume) is critical to facilitate the subsequent steps of purification.
- the capture step is commonly achieved by using chromatography with an ion- exchange resin.
- the drawback of using an ion-exchange resin is that the conductivity and/or pH of the loading has to be adjusted. When the conductivity is adjusted, in most instances reduced, it is performed by addition of water which increases the volume of the starting material, making it impractical for subsequent steps and overall cumbersome for production purposes. Furthermore, adjustment of pH often results in the formation of aggregates which could interfere with the performance of the purification steps.
- the polishing step refers to a final purification step, wherein trace contaminants and impurities are removed and the yield is an active biological product. Contaminants removed during the polishing step are often conformers of the target molecule or suspected leakage products.
- the method of the present invention is advantageous in that it, in a single step, provides a volume reduction and a considerable increase in specific activity.
- the method in a single step, combines a capture and a purification step.
- the present invention also provides an efficient process for producing a highly concentrated and very pure solution of recombinant Factor VIII wherein the Factor VIII protein is stabilized against degradation.
- the instant invention is related to the novel and efficient purification of recombinant proteins, especially coagulation factor VIII.
- the inventors of the present invention have found that use of multimodal columns for the capture of factor VIII molecules from mammalian cell culture fluid is a surprisingly fast and efficient purification method for removing contaminants from FVIII protein harvested from the culture, without the loss in the activity of the protein.
- the invention provides a method of purifying a coagulation Factor VIII protein containing one or more contaminants, the method comprising the steps of:
- the method further comprises a step (c) wherein the Factor VIII- containing solution resulting from step (b) is collected; and/or the method further comprising a step (al) wherein the column, subsequent to step (a) and before step (b), is passed with one or more wash buffer(s).
- one or more of said wash buffer(s) comprise(s) 1OmM to 100OmM salt
- the elution buffer of step (b) contains at least 2M salt and at least 45% (w/v) of ethylene glycol, propylene glycol, or a mixture thereof, such as, e.g. 2.3-2.6 M salt and 48-52% (w/v) of ethylene glycol, propylene glycol, or a mixture thereof
- the salt contained in the elution buffer of step (b) is selected from: NaCI, NH 4 CI, KCI, (NH 4 ) 2 SO 4 , CH 3 CO 2 NH 4, or a mixture of two or more of these.
- the invention provides a single step method of purifying a Factor VIII protein containing one or more contaminants, comprising the steps of: a) contacting the protein with a multi-modal resin containing the ligands which comprise a hydrophobic part and a negatively charged part; b) eluting the said protein with an elution buffer containing at least 1.5 M salt and at least 40% (w/v) of ethylene glycol, propylene glycol, or a mixture thereof, and calcium ions; wherein the said method achieves a reduction in the column volume of about 250-fold.
- the invention provides a single step method of purifying a Factor VIII protein containing one or more contaminants, comprising the steps of: a) contacting the protein with a multi-modal resin containing the ligands which comprise a hydrophobic part and a negatively charged part; b) eluting the said protein with an elution buffer containing at least 1.5 M salt and at least 40% (w/v) of ethylene glycol, propylene glycol, or a mixture thereof, and calcium ions; wherein the said method achieves a "purification factor" of at least 30-fold.
- the invention provides a method for stabilizing a Factor VIII protein, comprising the steps of: a) contacting the protein with a multi-modal resin containing the ligands which comprise a hydrophobic part and a negatively charged part; b) eluting the said protein with an elution buffer containing at least 1.5 M salt and at least 40% (w/v) of ethylene glycol, propylene glycol, or a mixture thereof, and calcium ions.
- Figure IA is a chromatogram showing the UV absorption at 280nm, conductivity and pH over a purification run with equilibration, loading, wash and elution.
- Figure IB shows an enlargement of the wash and elution part of the chromatogram of Figure 1.
- Figure 2 shows a silver-stained SDS gel electrophoresis illustrating the purification obtained using the Capto MMC column in the purification steps of loading, flow through (FT) and elution.
- Lanel MW standard
- Lane 2 Cell culture medium
- Lane 3 Empty
- Lane 4 Break through (not bound material) from the Capto MMC column
- Lane 5 Empty
- Lane 6 Capture pool (protein material bound and eluted from the Capto MMC column
- Figure 3 is a histogram showing the percentage yields of recombinant Factor VIII purified using Capto MMC resin with different elution buffers containing various concentrations of NaCI or NH 4 CI and ethylene glycol.
- Figure 4 shows the effect of repeated freeze/thaw cycles on the stability of the Factor VIII in the capture pool.
- the present method of purifying coagulation factor VIII is performed by using multimodal chromatography making use of resins that are both hydrophobic and negatively charged.
- the solution of the protein to be purified e.g. the protein-containing supernatant obtained from mammalian cell fermentation, is applied to the multimodal resin by passing a solution over a chromatography column containing said resin.
- the solution (loading) is typically filtered (e.g. by dead-end filtration or cross flow filtration) and/or centrifuged to remove cells and particles before being loaded onto the resin.
- the loading step does not require adjustment of pH or conductivity.
- the column is typically washed with one or more wash buffers, one of which containing high concentration of salt. In one embodiment, the column is washed, after loading, with equilibration buffer, optionally followed by wash with a second buffer with high concentration of salt.
- elution is performed by passing an elution buffer comprising a high concentration of salt and an organic solvent over the column.
- volume reduction is meant a reduction in the volume of protein-containing eluate solution when compared to the volume of protein-containing loading solution (e.g. the clarified crude sample from the fermentation process).
- the purification method of the invention further provides a protein yield of 70-100% and the purification factor (increase in the specific activity) is up to 100-fold.
- the resultant purified protein is stable in the elution buffer for at least 2 months at -70 0 C.
- the method of the invention provides a stable factor VIII solution :
- the capture eluate can be frozen and thawed at least 3 times without significantly loss of activity.
- the invention makes use of multi-modal chromatography resins for the separation of the factor VIII protein of interest from the contaminants.
- the multi-modal chromatography wherein two or more different, but co-operative, sites interact with a target, has been determined to be an appropriate system for purification of factor VIII protein.
- the chromatography resin used for the purification of the recombinant protein in the present invention is commercially available, for example: Capto MMCTM (GE Healthcare) or MBI HyperCelTM (Pall, formerly BioSepra).
- Capto MMC contains a ligand with multimodal functionality that gives a different selectivity compared to traditional ion exchangers and also provides the possibility of binding proteins at salt concentrations as high as 0.5M to 1.0 M.
- the ligand herein exhibits diverse functionalities for interaction with the target molecule and thus offers ionic interaction, hydrogen bonding and hydrophobic interaction.
- the multimodal resin is Capto MMCTM.
- MBI HyperCelTM (Pall), yet another multimodal chromatography, is efficient in tackling stability problems and leakage from protein-based affinity columns. More specifically, MBI Hypercel R TM (Pall), an adsorbent comprising mercapto-benzimidazole-sulphonic acid ligands, provides hydrophobic as well as ionic interactions with a given protein. The hydrophobic interactions are assumed to be due to the aromatic ring system, while the ionic interactions should be due to the SO 3 - substituent, which is known as a strong cation exchanger. In addition, the nitrogen atoms of the aromatic system of the MBI ligand are chargeable under certain conditions, and can consequently provide ionic interactions with negatively charged groups,
- the contaminants are adsorbed to the multimodal ligands, and an essentially pure fraction of coagulation factor VIII is recovered by a subsequent selective elution.
- the capture step provides a purification factor (increase in specific activity) of at least 80 times, such as 80 to 100-fold, 90 to 100-fold or 100-160-fold
- the resulting capture pool comprises the factor VIII protein that is at least 10% pure, such as at least 20% or about 30% to 60%, such as 30% to 50%.
- the purity is defined at the amount of factor VIII protein in % (w/w) (e.g. as determined by ELISA) of the total amount of protein.
- the solution loaded to the multi-modal chromatography resin is a factor Vlll-containing harvest from mammalian cell fermentation.
- said harvest is filtered and/or centrifuged to remove cells and particles; in another embodiment the harvest is loaded to the resin without any adjustment of pH or conductivity of the loading solution.
- the present invention specifically encompasses a method wherein the loading step comprises loading the protein-containing loading solution onto the resin at a pH and conductivity similar to the pH and conductivity a factor Vlll-containing harvest from mammalian cell fermentation, optionally a filtered harvest.
- the Factor Vlll-containing harvest is stabilized by the addition of imidazol (such as, e.g., 1-10 mmol imidazol per L harvest). Due to the small amount and volume of added imidazol compared to the volume of the harvest, any change in pH and/or conductivity of the harvest is negligible.
- the harvest is then (i) filtered and/or centrifuged to remove cells and particles and (ii) loaded to the resin without further addition of chemicals.
- the method of the invention is typically performed in a number of steps: equilibration of column, loading and elution.
- One or more washing steps may be included after loading and before elution.
- the washing step(s) is/are typically done using at least one buffer containing a high concentration of salt.
- a wash step is employed using a buffer comprising 10 imM to 1000 imM salt, such as, e.g. 100-1000 imM, or 250-1000 imM, or 500- 1000 mM, or 500-800 mM salt.
- the method includes a washing step wherein, after loading, the column is first washed with equilibration buffer and then washed with a second washing buffer containing high salt.
- the equilibration buffer comprises a buffering agent (such as e.g. imidazole in the range of 5 mM to 100 mM, e.g. 2OmM Imidazole), a Ca-salt (1 mM to 100 mM, e.g. 10 mM CaCI 2 ,) a detergent (such as e.g. TweenTM 80 in the range of 0.001% to 0.1%, e.g. 0.02% (w/v) TweenTM 80) and a salt (10 mM to 1000 mM, e.g. 50 mM NaCI).
- a buffering agent such as e.g. imidazole in the range of 5 mM to 100 mM, e.g. 2OmM Imidazole
- Ca-salt 1 mM to 100 mM, e.g. 10 mM CaCI 2
- a detergent such as e.g. TweenTM 80 in the range of 0.001% to
- the equilibration buffer is maintained at a pH of 6.0 to 8.0; preferably the pH conditions are maintained at 7.3 to 7.5. It will be appreciated by a person skilled in the art that the factor VIII protein exemplified herein is stable at a pH of about 6.0 to 8.0 and thus the equilibration buffer is at a pH of 7.3 - 7.5, more preferably at 7.5.
- the wash buffer comprises a buffering agent (such as e.g. imidazole in the range of 5 mM to 100 mM, e.g. 2OmM Imidazole), a Ca-salt (1 mM to 100 mM, e.g.
- a detergent such as e.g. TweenTM 80 in the range of 0.001% to 0.1%, e.g. 0.02% (w/v) Tween 80
- a salt e.g. NaCI in the range of 50 mM to 1000 mM
- the elution step is performed with an elution buffer comprising at least 1.5 M salt and at least 40% (w/v) of ethylene glycol, propylene glycol or a mixture thereof, and calcium ions (1 mM to 100 mM, e.g. 10 mM CaCI 2) .
- the elution buffer has a pH of 6.0 to 8.0; preferably the pH conditions are maintained at 7.3 to 7.5. To maintain the desired pH conditions, the elution buffer also contains a buffering agent.
- buffering agent encompasses those agents which are able to maintain the pH of a solution within a desired range - in the context of the present invention within the range of 6.0 to 8.0, such as 7.3 to 7.5.
- the buffer concentration range is chosen to maintain the preferred pH of the solution.
- the buffering agent may also be a mixture of at least two buffering agents, wherein the mixture is able to provide a pH value in the specified range.
- Buffering agents may include, but are not limited to, citrate (sodium or potassium), acetate (ammonium, sodium or calcium), histidine (L-histidine), phosphate (sodium or potassium), tartaric acid, succinic acid, MES, HEPES, imidazol, TRIS, ethanolamine, and mixtures of two or more thereof.
- the buffering agent employed is imidazole in the range of 5 mM to 10O mM.
- Preferred salts are NaCI, NH 4 CI, KCI, (NH 4 ) 2 SO 4 , CH 3 CO 2 NH 4 (ammonium acetate, NH 4 Ac), or a mixture of two or more thereof.
- the elution buffer comprises about 2.5 M salt and at least 40% glycol; in another embodiment, the elution buffer comprises about 2.5M salt and about 50% glycol.
- the salt is NaCI; in another, the salt is NH 4 CI.
- the glycol is ethylene glycol; in another, the glycol is propylene glycol.
- the elution buffer comprises NaCI and ethylene glycol.
- NH 4 CI at a concentration of 2.5M with ethylene glycol is also used for elution of the protein.
- the elution buffer further comprises a detergent.
- the eluent is 2OmM Imidazole, 1OmM CaCI 2 , 0.02% (v/v) Tween 80, 2.5M NaCI and 8 M ethylene glycol at a pH of 7.5.
- MBI HyperCelTM resin is used in the method for purification of Factor VIII.
- binding of the recombinant factor VIII using the MBI HyperCelTM column is performed after addition of 10OmM Na 2 SO 4 to the harvest and elution is achieved with IM NaCI and 5M glycerol.
- the method comprises the steps of: a) contacting the Factor VIII with a multimodal or mixed mode resin containing the ligands which comprise a hydrophobic part and a negatively charged part; b) passing the column with equilibrating buffer comprising 2OmM Imidazole, 10 mM CaCI 2 , 0.02% (w/v) Tween 80 and 50 mM NaCI and wash buffer comprising of 2OmM Imidazole, 10 mM CaCI 2 , 0.02% (w/v) Tween 80 and 1.5M NaCI; c) eluting the said protein with elution buffer comprising 2OmM Imidazole, 10 mM CaCI 2 , 0.02% (v/v) Tween 80, 2.5M NaCI, and 8M ethylene glycol.
- the first step of the purification of a recombinant protein expressed in mammalian cells handles large loading volumes.
- it is important to reduce the volume to where it can be easily handled.
- the purification step has to have a significant yield to achieve process economy for commercial or other purposes.
- About 20 to 100 times reduction in volume in the first step is normally aimed at in the first step of the protein purification wherein the latter is regarded as a sound volume reduction.
- the loading volume containing the protein to be purified is above 500 column volumes (CV).
- the protein eluted provides a reduction in the final volume of more than 100-fold.
- the instant invention encompasses a loading volume of 50-600 CV.
- the reduction in volume is preferably about 100-300 times.
- the loading volume is about 500 CV, or about 450-600 CV, and the factor VIII protein is eluted in about 2CV achieving a volume reduction of about 250 times.
- the capture step can be combined with one or more virus inactivating agents, such as e.g. Triton X-100 (for example in a concentration of about 1% (w/v).
- virus inactivating agent may e.g. be added to one or more of the used buffers.
- Flow rates are manipulated to be between 300-950cm/hr for all steps of the purification process except elution and clean-in-place (CIP) steps where flow rates are at 30-350cm/h.
- the flow rate at loading is 450cm/h; during elution and CIP, the flow rate is decreased to 30cm/h. In one embodiment of the invention, the flow rate at loading is about 450-600cm/h.
- the invention also relates to a preparation comprising :
- a Factor VIII protein (i) a Factor VIII protein; and (ii) a buffer containing at least 1.5 M salt and at least 40% (w/v) of ethylene glycol, propylene glycol, or a mixture thereof, and calcium ions; wherein the Factor VIII is 30% to 60% pure.
- Fractor VIII protein is meant to include full-length factor VIII, FVIII: C, and deletion derivatives of full-length factor VIII having coagulant activity.
- deletion derivative it is meant factor VIII wherein the whole or part of the B-domain is missing while the coagulant activity is retained.
- B-domain deleted forms of Factor VIII are, for example, described in WO91/09122. The structure and biochemistry of Factor VIII in general have been described by Kaufman (Trends in Biotechnology, 9, p.353-359 (1991) and Hematology, 63, p.155-165 (1991)).
- factor VIII sequence variants and derivatives including pegylated, acylated, and polysialylated forms of factor VIII, having maintained the characteristic factor VIII biological activity.
- the factor VIII may be obtained by recombinant means.
- the factor VII is recombinantly produced factor VIII.
- the Factor VIII is full length Factor VIII; in another embodiment, the Factor VIII protein is a B-domain deleted Factor VIII.
- the factor VIII is a pegylated, acylated, or polysialylated Factor VIII.
- Factor VIII concentrates derived from human plasma contain several fragmented fully active Factor VIII forms as described by Andersson et al (Proc. Natl. Acad. Sci.
- the smallest active form has a molecular mass of 170 kDa and consists of two chains of 90 kDa and 80 kDa held together by metal ion(s) (see, e.g. EP197901).
- metal ion(s) see, e.g. EP197901.
- Such Factor VIII fragments are also included - purification of such fragments constitute one embodiment of the present invention.
- Biological activity of factor VIII are assayed, e.g., as described in Experimental section (see below).
- the term "eluent” is meant in its conventional meaning as it is identified in the art which is a buffer or buffers of suitable pH and/or ionic strength to release one or more proteins or compounds from a separation matrix.
- the "salt" in the elution step refers to an alkaline earth, alkali metal, or ammonium salt, i.e., a salt having a cation from the alkaline earth or alkali metal elements or an ammonium cation and having an inorganic or organic (hydrocarbon-based) anion.
- salts include sodium chloride, ammonium chloride, sodium citrate, potassium citrate, potassium chloride, magnesium chloride, calcium chloride, sodium phosphate, calcium phosphate, ammonium phosphate, magnesium phosphate, potassium phosphate, sodium sulfate, ammonium sulfate, potassium sulfate, magnesium sulfate, calcium sulfate, etc.
- Preferred salts herein are chlorides or sulfates. The most preferred salt herein is sodium chloride.
- multi-modal chromatography ligand refers to a ligand that is capable of providing at least two different, but co-operative, sites which interact with the protein to be bound. One of these sites gives an attractive type of charge-charge interaction between the ligand and the substance of interest. The other site typically gives electron acceptor-donor interaction and/or hydrophobic and/or hydrophilic interactions.
- the present invention is directed, particularly to the hydrophobic interactions. Electron donor-acceptor interactions include interactions such as hydrogen-bonding, .pi. -.pi., cation-. pi., charge transfer, dipole- dipole, induced dipole etc.
- Multi-modal chromatography ligands as used herein or elsewhere are also known as "mixed mode" chromatography ligands.
- capture step refers, in the context of liquid chromatography, to the initial step of a separation procedure. Most commonly, a capture step includes clarification, concentration, stabilization and a significant purification from soluble contaminants. After the capture step, an intermediate purification may follow, which removes most of the significant impurities including DNA, viruses and endotoxins. These impurities can also be remove/reduced in capture.
- polishing step refers to a final purification step, wherein trace contaminants and impurities are removed and the yield is an active biological product. Contaminants removed during the polishing step are often conformers of the target molecule or suspected leakage products.
- Column Volume refers to the geometric volume of the part of the tube that contains the packing. As per the instant invention, the loading volume is above 50 Column Volumes (CV) or more or less about 300-600 CV or 450- 600 CV.
- the protein eluted at the final step of purification is about 2-5 CV achieving a volume reduction of about 100-fold to 350-fold, such as, e.g., 250-fold.
- the "purification factor” is defined as increase in specific activity: That is U/mg protein before the purification step compared to U/mg protein after the purification step.
- the specific activity of coagulation factor VIII may be assayed by commercially available activity assays, such as, for example, using CoaTest ® ChromogenixTM (Instrumentation Laboratory, Belgium) according to the manufacturer's protocol or as described in the Experimentals section, below.
- a single step method refers to a method of purifying a Factor VIII protein containing one or more contaminants, wherein the method achieves both a reduction in volume and an increase in specific activity (purification factor > 1).
- the method provides (i) a reduction in the column volume of about 250-fold, and (ii) a "purification factor" of at least 30-fold.
- factor VIII isolation of factor VIII as well as recombinant production of factor VIII (full- length and variants/truncated forms) are described in the art:
- Recombinant DNA technology has allowed construction of plasmids that direct the expression of fusion products of Factor VIII protein in transfected mammalian cells.
- B domain is missing and/or specific amino acid positions are modified, for example, such that normally protease-labile sites are resistant to proteolysis, e.g. by thrombin or activated Protein C.
- Other analogs include modification at one or more lysine and/or tyrosine residues.
- the truncated form of the protein is a 170 kDa glycoprotein consisting of 1438 amino acids.
- This B-domain deleted protein is a post- translational modification of the plasma-derived Factor VIII and is comparable in its antihemophilic activity to that of the parent.
- the activity of purified Factor VIII may e.g. be assayed using CoaTest ® ChromogenixTM (Instrumentation Laboratory, Belgium) according to the manufacturer's protocol.
- the recombinant Factor VIII was expressed in CHO-cells in a commercially available serum free media.
- the protein harvest from the fermentation was further used for the purification.
- Capto MMC (GE Healthcare, Uppsala, Sweden) resin was used for the purification of the recombinant protein.
- the column was packed with a bed height of 12cm and 24ml bed volume.
- the purification process involved loading wherein the harvest from the fermentation was applied onto the column.
- the column volume (CV) of loading was 450CV (Table 1). This was followed by passing the column with equilibration buffer consisting of 2OmM imidazole, 1OmM CaCI2, 0.02% (v/v) Tween 80 and 5OmM NaCI. The pH of the equilibration buffer is adjusted to 7.5. The column is further washed with wash buffer (2OmM imidazole, 1OmM CaCI2, 0.02% (v/v) Tween 80 and 1.5M NaCI) at a pH equivalent to the equilibration buffer, i.e. 7.5. The column volumes of equilibration and washing steps were 3CV (Table 1).
- Elution buffer consists of
- Flow rate was maintained at 450cm/h at every step of purification except the elution and CIP during which the flow rate was 30cm/h.
- the activity of purified Factor VIII was measured using a modification of the CoaTest ® SP assay:
- Reagents and buffer stock solution from the CoaTest ® SP kit were used. All reagents were allowed to reach room temperature before initiation of experiment. Samples were diluted in CoaTest assay buffer (50 imM Tris, 150 imM NaCI, 1 % BSA, pH 7.3, with preservative) to approximately 2 mU/ml. The reference plasma was diluted in assay buffer to 5 - 0.5 mU/ml. The samples were diluted in assay buffer to 12 and 9 U/ml, then 10-fold in FVIII-deficient plasma with VWF (Dade Behring), and finally 10- and 20-fold in CoaTest ® assay buffer (resulting in 4 dilutions per sample).
- CoaTest assay buffer 50 imM Tris, 150 imM NaCI, 1 % BSA, pH 7.3, with preservative
- the reference plasma was diluted in assay buffer to 5 - 0.5 mU/ml.
- the samples were diluted in assay buffer to 12
- the absorbance at 415 nm was measured on a Spectramax ® microtiter plate reader (Molecular Devices) with absorbance at 620 nm used as reference wavelength.
- the value for the negative control was subtracted from all samples and a calibration curve prepared by linear regression of the absorbance values plotted vs. FVIII concentration in mU/ml.
- Factor VIII antigen was determined using the commercial ELISA kit from Affinity Biologicals (VisuLize Factor VIII Antigen Kit, Lot AG8-0006) essentially as described by the manufacturer.
- Recombinant Factor VIII was purified from the fermentation harvest as described in Example 2, above. Purification factor and yield of Factor VIII protein was determined by CoA and ELISA as described above:
- SDS gel electrophoresis was carried out using 7% NuPage ® tris acetate gel with tris acetate as running buffer essentially as described by the manufacturer (Invitrogen). Briefly, the gel electrophoresis was carried out for 50 min at 150 volt and the samples were stained with SilverQuest ® staining kit (Invitrogen) as described in the manufacturer's instructions. The molecular weight (MW) standards used were Mark 12 from Invitrogen.
- Protein samples for electrophoresis were denatured and reduced at 70 0 C for 10 min in LDS sample buffer (Invitrogen) containing 50 mM DTT. Separation gels were 7% tris-acetate (TA) Pre-Cast Novex polyacrylamide gel (Invitrogen) and electrophoresis was carried out for 60 min at a limiting voltage of 150 V and with tris-acetate buffer (Invitrogen) as both anode and cathode buffer. Silver staining was carried out using SilverQuest ® (Invitrogen) according to the manufacturer's description. The gel illustrate the large purification obtained using the Capture MMC column. The cell medium contains a series of proteins. The large majority of these protein pass through the column whereas the Factor VIII is highly concentrated in the capture pool from the column.
- Elution buffer of 2OmM ethanolamine, 1OmM CaCI 2 , Tween 80 (0.2%v/v), at pH 8.3 with different salt and ethylene glycol concentrations were used which include: a. no addition; b. IM NH 4 CI; c. 2.5M NH 4 CI; d. 3M ethylene glycol; e. IM NH 4 CI + 3M ethylene glycol; f. 2.5M NH 4 CI + 3M ethylene glycol; g. 8M ethylene glycol; h. IM NH 4 CI + 8M ethylene glycol; I. 2.5M NH 4 CI + 8M ethylene glycol; 2.5M NaCI + 8M ethylene glycol.
- the elution conditions were determined based on the percentage yield.
- Figure 3 shows that at concentrations of 2.5M NH 4 CI or 2.5M NaCI and 8M ethylene glycol, the percentage yield of the protein was maximum (Figure 3).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08786090A EP2167526B1 (fr) | 2007-07-11 | 2008-07-11 | Purification du facteur viii à l'aide d'une résine en mode mixte ou multimodal |
PL08786090T PL2167526T3 (pl) | 2007-07-11 | 2008-07-11 | Oczyszczanie czynnika VIII za pomocą żywicy o mieszanej funkcji lub wielofunkcyjnej |
NL300663C NL300663I2 (fr) | 2007-07-11 | 2014-04-15 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07112287 | 2007-07-11 | ||
EP08786090A EP2167526B1 (fr) | 2007-07-11 | 2008-07-11 | Purification du facteur viii à l'aide d'une résine en mode mixte ou multimodal |
PCT/EP2008/059094 WO2009007451A1 (fr) | 2007-07-11 | 2008-07-11 | Purification du facteur viii à l'aide d'une résine en mode mixte ou multimodal |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2167526A1 true EP2167526A1 (fr) | 2010-03-31 |
EP2167526B1 EP2167526B1 (fr) | 2011-03-30 |
Family
ID=38472947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08786090A Active EP2167526B1 (fr) | 2007-07-11 | 2008-07-11 | Purification du facteur viii à l'aide d'une résine en mode mixte ou multimodal |
Country Status (15)
Country | Link |
---|---|
US (1) | US8399620B2 (fr) |
EP (1) | EP2167526B1 (fr) |
JP (1) | JP5323072B2 (fr) |
KR (1) | KR101293504B1 (fr) |
CN (1) | CN101730707B (fr) |
AT (1) | ATE503763T1 (fr) |
AU (1) | AU2008274195B2 (fr) |
BR (1) | BRPI0814220B8 (fr) |
CA (1) | CA2692814A1 (fr) |
DE (1) | DE602008005885D1 (fr) |
ES (1) | ES2364118T3 (fr) |
NL (1) | NL300663I2 (fr) |
PL (1) | PL2167526T3 (fr) |
RU (1) | RU2493163C2 (fr) |
WO (1) | WO2009007451A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11203747B2 (en) | 2012-10-24 | 2021-12-21 | Genzyme Corporation | Elution of biomolecules from multi-modal resins using MES and MOPS as mobile phase modifiers |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5619738B2 (ja) * | 2008-06-24 | 2014-11-05 | オクタファルマ アクチェンゲゼルシャフト | 凝固第viii因子の精製方法 |
MX2011001624A (es) | 2008-08-21 | 2011-03-28 | Octapharma Ag | Factor viii y ix humano producido en forma recombinante. |
US8945895B2 (en) | 2009-07-31 | 2015-02-03 | Baxter International Inc. | Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof |
US8277649B2 (en) | 2009-12-14 | 2012-10-02 | General Electric Company | Membranes and associated methods for purification of antibodies |
US8974780B2 (en) | 2010-02-24 | 2015-03-10 | Zymenex A/S | Process for production and purification of recombinant lysosomal alpha-mannosidase |
RU2015149979A (ru) | 2010-03-30 | 2019-01-15 | Октафарма Аг | Способ очистки белка фактора роста |
WO2011121020A1 (fr) | 2010-03-30 | 2011-10-06 | Octapharma Ag | Procédé de purification de protéines dépendantes de la vitamine k telles que le facteur de coagulation ix |
US9422329B2 (en) | 2010-11-05 | 2016-08-23 | Hoffmann-La Roche Inc. | Optimized method for antibody capturing by mixed mode chromatography |
CA2821711C (fr) | 2010-12-15 | 2017-10-10 | Baxter International Inc. | Recuperation d'eluat par utilisation d'un gradient de conductivite |
WO2013075740A1 (fr) | 2011-11-23 | 2013-05-30 | Sanofi | Procédé de purification d'anticorps |
US10188965B2 (en) | 2012-12-05 | 2019-01-29 | Csl Behring Gmbh | Hydrophobic charge induction chromatographic depletion of a protein from a solution |
US20140154233A1 (en) | 2012-12-05 | 2014-06-05 | Csl Limited | Method of purifying therapeutic proteins |
CN103396494B (zh) * | 2013-04-27 | 2015-04-01 | 江苏省疾病预防控制中心 | 一种凝血因子ix的单克隆抗体 |
TWI631132B (zh) | 2013-05-06 | 2018-08-01 | 賽諾菲公司 | 用於純化抗體之連續多步驟方法 |
TW201617360A (zh) * | 2014-06-25 | 2016-05-16 | 桂格 史考特 布蘭克 | 用於純化蛋白質之方法及試劑 |
MX2017000862A (es) | 2014-08-04 | 2017-05-01 | Csl Ltd | Formulacion de factor viii. |
DK3265483T3 (da) | 2015-03-06 | 2020-03-02 | CSL Behring Lengnau AG | Modificeret von Willebrand-faktor med forbedret halveringstid |
GB201506117D0 (en) | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
GB201506113D0 (en) | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
EP3205665A1 (fr) * | 2016-02-11 | 2017-08-16 | Octapharma AG | Procédé de séparation de facteur viii à partir de produits sanguins |
GB201617240D0 (en) * | 2016-10-11 | 2016-11-23 | Profactor Pharma Ltd | Purification process |
CN111183151B (zh) | 2017-06-23 | 2024-06-07 | 武田药品工业株式会社 | 因子viii亚种的纯化 |
KR20220029733A (ko) | 2019-07-04 | 2022-03-08 | 체에스엘 베링 렝나우 아게 | 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf) |
JP2023500953A (ja) | 2019-11-11 | 2023-01-11 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 第viii因子に対する寛容を誘導するためのポリペプチド |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9302006D0 (sv) * | 1992-10-02 | 1993-06-11 | Kabi Pharmacia Ab | Protein formulation |
SE9301581D0 (sv) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Protein formulation |
SE503424C2 (sv) * | 1994-11-14 | 1996-06-10 | Pharmacia Ab | Process för rening av rekombinant koagulationsfaktor VIII |
IL157309A0 (en) * | 2003-08-07 | 2004-02-19 | Applied Research Systems | Method for the purification of a non-immunoglobulin protein |
EP1831242B1 (fr) * | 2004-12-23 | 2012-09-26 | Novo Nordisk Health Care AG | Reduction du contenu en contaminants proteiques de compositions renfermant une proteine d'interet dependante de la vitamine k |
EP1707634A1 (fr) | 2005-03-29 | 2006-10-04 | Octapharma AG | Procédé pour l'isolation de protéines recombinantes |
JP5619738B2 (ja) | 2008-06-24 | 2014-11-05 | オクタファルマ アクチェンゲゼルシャフト | 凝固第viii因子の精製方法 |
-
2008
- 2008-07-11 PL PL08786090T patent/PL2167526T3/pl unknown
- 2008-07-11 CN CN200880023645.XA patent/CN101730707B/zh active Active
- 2008-07-11 KR KR1020107001510A patent/KR101293504B1/ko active IP Right Grant
- 2008-07-11 WO PCT/EP2008/059094 patent/WO2009007451A1/fr active Application Filing
- 2008-07-11 EP EP08786090A patent/EP2167526B1/fr active Active
- 2008-07-11 ES ES08786090T patent/ES2364118T3/es active Active
- 2008-07-11 CA CA 2692814 patent/CA2692814A1/fr not_active Abandoned
- 2008-07-11 JP JP2010515524A patent/JP5323072B2/ja active Active
- 2008-07-11 US US12/668,530 patent/US8399620B2/en active Active
- 2008-07-11 RU RU2010103528/10A patent/RU2493163C2/ru active
- 2008-07-11 AU AU2008274195A patent/AU2008274195B2/en not_active Ceased
- 2008-07-11 BR BRPI0814220A patent/BRPI0814220B8/pt not_active IP Right Cessation
- 2008-07-11 DE DE602008005885T patent/DE602008005885D1/de active Active
- 2008-07-11 AT AT08786090T patent/ATE503763T1/de not_active IP Right Cessation
-
2014
- 2014-04-15 NL NL300663C patent/NL300663I2/nl unknown
Non-Patent Citations (1)
Title |
---|
See references of WO2009007451A1 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11203747B2 (en) | 2012-10-24 | 2021-12-21 | Genzyme Corporation | Elution of biomolecules from multi-modal resins using MES and MOPS as mobile phase modifiers |
Also Published As
Publication number | Publication date |
---|---|
RU2010103528A (ru) | 2011-08-20 |
BRPI0814220B8 (pt) | 2021-05-25 |
AU2008274195A1 (en) | 2009-01-15 |
DE602008005885D1 (de) | 2011-05-12 |
BRPI0814220A2 (pt) | 2015-01-06 |
KR20100051620A (ko) | 2010-05-17 |
AU2008274195B2 (en) | 2013-09-05 |
ES2364118T9 (es) | 2014-05-19 |
JP2010533150A (ja) | 2010-10-21 |
US20100204452A1 (en) | 2010-08-12 |
CN101730707A (zh) | 2010-06-09 |
CA2692814A1 (fr) | 2009-01-15 |
KR101293504B1 (ko) | 2013-08-07 |
CN101730707B (zh) | 2014-12-17 |
JP5323072B2 (ja) | 2013-10-23 |
US8399620B2 (en) | 2013-03-19 |
BRPI0814220B1 (pt) | 2019-09-17 |
ATE503763T1 (de) | 2011-04-15 |
RU2493163C2 (ru) | 2013-09-20 |
PL2167526T3 (pl) | 2011-09-30 |
NL300663I2 (fr) | 2016-09-22 |
EP2167526B1 (fr) | 2011-03-30 |
WO2009007451A1 (fr) | 2009-01-15 |
ES2364118T3 (es) | 2011-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008274195B2 (en) | Purification of factor VIII using a mixed-mode or multimodal resin | |
KR101804136B1 (ko) | 응고 인자 viii을 정제하는 방법 | |
Burnouf‐Radosevich et al. | Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate | |
JP3110292B2 (ja) | フォンウィルブランド因子の高分子および低分子フラクション | |
EP1863920A1 (fr) | Procédé d'isolation ameliorée des protéines de recombinaison | |
US11479578B2 (en) | Protein purification and virus inactivation with alkyl glycosides | |
US6307032B1 (en) | Highly purified factor VIII complex | |
AU747274B2 (en) | Improved methods for producing factor VIII proteins | |
KR20070091098A (ko) | 단백질 분리 방법 | |
JP7144113B2 (ja) | 血液製剤から第viii因子を分離する方法 | |
US20210087224A1 (en) | Compositions and methods for generating modified cryo poor plasma | |
CA2251558C (fr) | Complexe du facteur viii hautement purifie | |
EA040179B1 (ru) | Способ очистки fviii или его варианта с удаленным доменом b от клеточной культуры in vitro | |
EP3526245A1 (fr) | Procédé de purification de fviii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100211 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 602008005885 Country of ref document: DE Date of ref document: 20110512 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008005885 Country of ref document: DE Effective date: 20110512 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110330 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110701 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110330 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110330 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20110330 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2364118 Country of ref document: ES Kind code of ref document: T3 Effective date: 20110825 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110330 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110330 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110330 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110630 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110330 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110330 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110801 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110330 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110330 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110330 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110330 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110730 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110330 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110330 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110731 |
|
26N | No opposition filed |
Effective date: 20120102 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008005885 Country of ref document: DE Effective date: 20120102 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110711 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110711 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110330 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: SPCF Free format text: PRODUCT NAME: TUROCTOCOG ALFA, IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/13/888 20131113 Spc suppl protection certif: C300663 Filing date: 20140415 Extension date: 20281112 |
|
REG | Reference to a national code |
Ref country code: IT Ref legal event code: SPCF Ref document number: 502011901957948 Country of ref document: IT Free format text: PRODUCT NAME: TUROCTOCOG ALFA(NOVOEIGHT); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/888, 20131113 Spc suppl protection certif: 132014902257593 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CP Free format text: PRODUCT NAME: TUROCTOCOG ALFA; REGISTRATION NO/DATE: EU/1/13/888 20131113 Spc suppl protection certif: 14C0037 Filing date: 20140509 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: SPCF Free format text: PRODUCT NAME: TUROKTOKOG ALFA; REG. NO/DATE: EU/1/13/888 20131113 Spc suppl protection certif: 1490031-0 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: CTFF Free format text: PRODUCT NAME: TUROTOCOG ALFA; REGISTERED: UK EU/01/13/888 20131115 Spc suppl protection certif: SPC/GB14/038 Filing date: 20140508 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CP Free format text: PRODUCT NAME: TUROCTOCOG ALFA; REGISTRATION NO/DATE: EU/1/13/888 20131113 Spc suppl protection certif: 14C0037 Filing date: 20140509 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R065 Ref document number: 602008005885 Country of ref document: DE Free format text: PRODUCT NAME: TUROCTOCOG ALFA; REGISTRATION NO/DATE: EU/1/13/888 20131113 Spc suppl protection certif: 122014000053 Filing date: 20140508 Expiry date: 20280712 Effective date: 20140530 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCF Free format text: PRODUCT NAME: TUROCTOCOG ALFA; REGISTRATION NO/DATE: SWISSMEDIC 63014 18.02.2014 Filing date: 20140715 |
|
REG | Reference to a national code |
Ref country code: IT Ref legal event code: SPCG Ref document number: 502011901957948 Country of ref document: IT Free format text: PRODUCT NAME: TUROCTOCOG ALFA(NOVOEIGHT); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/888, 20131113 Spc suppl protection certif: 132014902257593 Extension date: 20281112 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: SPCG Free format text: PRODUCT NAME: TUROKTOKOG ALFA; REG. NO/DATE: EU/1/13/888 20131113 Spc suppl protection certif: 1490031-0 Expiry date: 20280712 Extension date: 20281112 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CT Free format text: PRODUCT NAME: TUROCTOCOG ALFA; REGISTRATION NO/DATE: EU/1/13/888 20131113 Spc suppl protection certif: 14C0037 Filing date: 20140509 Extension date: 20281113 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CT Free format text: PRODUCT NAME: TUROCTOCOG ALFA; REGISTRATION NO/DATE: EU/1/13/888 20131113 Spc suppl protection certif: 14C0037 Filing date: 20140509 Extension date: 20281113 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: AV Effective date: 20150625 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCG Free format text: PRODUCT NAME: TUROCTOCOG ALFA; REGISTRATION NO/DATE: SWISSMEDIC 63014 18.02.2014 Spc suppl protection certif: C02167526/01 Filing date: 20140715 Extension date: 20290217 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: SPCG Free format text: PRODUCT NAME: TUROCTOCOG ALFA; REGISTRATION NO/DATE: EU/1/13/888 20131115 Spc suppl protection certif: 300663 Filing date: 20140415 Expiry date: 20280710 Extension date: 20281114 Effective date: 20160922 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20200624 Year of fee payment: 13 Ref country code: CH Payment date: 20200623 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20200626 Year of fee payment: 13 Ref country code: NL Payment date: 20200625 Year of fee payment: 13 Ref country code: PL Payment date: 20200625 Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20210801 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210731 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210712 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210801 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCL Spc suppl protection certif: C02167526/01 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210711 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20230801 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240620 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240619 Year of fee payment: 17 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210711 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20240619 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240619 Year of fee payment: 17 |